As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The number of COVID-19 vaccination doses administered per 100 people in Ireland rose to 221 as of Oct 27 2023. This dataset includes a chart with historical data for Ireland Coronavirus Vaccination Rate.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows. https://covid-19.geohive.ie/pages/helpfaqs Category Field label Field Name Explanation

ExtractDate Extract Date Date the data is Extracted

Latitude Latitude

Longitude Longitude

VaccinationDate Vaccination Date Date the Vaccination occurred

Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

TotalDailyVaccines Total Daily Vaccines

Gender Male

Female

NA

Dose Number Dose1 Dose 1

Dose2 Dose 2

SingleDose Single Dose

Vaccine Brand Moderna

Pfizer

Janssen

AstraZeneca

Age Group Partial_Age0to9 At Least One Dose Age 0 to 11 Dose 1 of Astrazenenca, MRNA or Single Dose Vaccine

Partial_Age10to19 At Least One Dose Age 12 to 19

Partial_Age20to29 At Least One Dose Age 20 to 29

Partial_Age30to39 At Least One Dose Age 30 to 39

Partial_Age40to49 At Least One Dose Age 40 to 49

Partial_Age50to59 At Least One Dose Age 50 to 59

Partial_Age60to69 At Least One Dose Age 60 to 69

Partial_Age70to79 At Least One Dose Age 70 to 79

Partial_Age80+ At Least One Dose Age80+

Partial_NA At Least One Dose Not Assigned

Age Group Cumulative ParCum_Age0to9 Cumulative Age 0 to 11 Cumulative At least One Dose Age 0 to 11

ParCum_Age10to19 Cumulative Age 12 to 19 Cumulative At least One Dose Age 12 to 19

ParCum_Age20to29 Cumulative Age 20 to 29 Cumulative At least One Dose Age 20 to 29

ParCum_Age30to39 Cumulative Age 30 to 39 Cumulative At least One Dose Age 30 to 39

ParCum_Age40to49 Cumulative Age 40 to 49 Cumulative At least One Dose Age 40 to 49

ParCum_Age50to59 Cumulative Age50 to 59 Cumulative At least One Dose Age 50 to 59

ParCum_Age60to69 Cumulative Age 60 to 69 Cumulative At least One Dose Age 60 to 69

ParCum_Age70to79 Cumulative Age 70 to 79 Cumulative At least One Dose Age 70 to 79

ParCum_80+ Cumulative Age 80+ Cumulative At least One Dose Age 80+

Age Group Cumulative Percent ParCum_NA Cumulative Age Not Assigned Cumulative At least One Dose Age Not Assigned

ParPer_Age0to9 At Least One Dose Percent Age 0 to 11 Cumulative At least One Dose Age cohort/ Age cohort population

ParPer_Age10to19 At Least One Dose Percent Age 12 to 19

ParPer_Age20to29 At Least One Dose Percent Age 20 to 29

ParPer_Age30to39 At Least One Dose Percent Age 30 to 39

ParPer_Age40to49 At Least One Dose Percent Age 40 to 49

ParPer_Age50to59 At Least One Dose Percent Age 50 to 59

ParPer_Age60to69 At Least One Dose Percent Age 60 to 69

ParPer_Age70to79 At Least One Dose Percent Age 70 to 79

ParPer_80+ At Least One Dose Percent 80+

ParPer_NA At Least One Dose Percent Not Assigned

Age Group Fully_Age0to9 Fully vaccinated Age 0 to 11 Dose 2 of An MRNA or AztraZeneca Vaccine or a single dose vaccine of a Janssen

Fully_Age10to19 Fully vaccinated Age 12 to 19

Fully_Age20to29 Fully vaccinated Age 20 to 29

Fully_Age30to39 Fully vaccinated Age 30 to 39

Fully_Age40to49 Fully vaccinated Age 40 to 49

Fully_Age50to59 Fully vaccinated Age 50 to 59

Fully_Age60to69 Fully vaccinated Age 60 to 69

Fully_Age70to79 Fully vaccinated Age 70 to 79

Fully_Age80+ Fully vaccinated Age 80+

Fully_NA Fully vaccinated Age Not Available

Age Group Cumulative FullyCum_Age0to9 Cumulative Fully vaccinated Age 0 to 11

FullyCum_Age10to19 Cumulative Fully vaccinated Age 12 to 19

FullyCum_Age20to29 Cumulative Fully vaccinated Age 20 to 29

FullyCum_Age30to39 Cumulative Fully vaccinated Age 30 to 39

FullyCum_Age40to49 Cumulative Fully vaccinated Age 40 to 49

FullyCum_Age50to59 Cumulative Fully vaccinated Age 50 to 59

FullyCum_Age60to69 Cumulative Fully vaccinated Age 60 to 69

FullyCum_Age70to79 Cumulative Fully vaccinated Age 70 to 79

FullyCum_80+ Cumulative Fully vaccinated Age 80+

Age Group Cumulative Percent FullyCum_NA Cumulative Fully vaccinated Age Not Available

FullyPer_Age0to9 Cumulative Percent Fully vaccinated Age 0 to 11 Cumulative Fully Vaccinated Age cohort/ Age cohort population

FullyPer_Age10to19 Cumulative Percent Fully vaccinated Age 12 to 19

FullyPer_Age20to29 Cumulative Percent Fully vaccinated Age 20 to 29

FullyPer_Age30to39 Cumulative Percent Fully vaccinated Age 30 to 39

FullyPer_Age40to49 Cumulative Percent Fully vaccinated Age 40 to 49

FullyPer_Age50to59 Cumulative Percent Fully vaccinated Age 50 to 59

FullyPer_Age60to69 Cumulative Percent Fully vaccinated Age 60 to 69

FullyPer_Age70to79 Cumulative Percent Fully vaccinated Age 70 to 79

FullyPer_80+ Cumulative Percent Fully vaccinated Age 80+

FullyPer_NA Cumulative Percent Fully vaccinated Age Not Available

This feature layer represents Sustainable Development Goal indicator 3.b.1 'Proportion of Population Covered by Vaccines by Type of Vaccine' for Ireland. The layer was created using Annual Epidemiological Report 2015 data produced by the Health Protection Surveillance Centre and pre 2014 Administrative County boundary data (more info) produced by Tailte Éireann. In 2015 UN countries adopted a set of 17 goals to end poverty, protect the planet and ensure prosperity for all as part of a new sustainable development agenda. Each goal has specific targets to help achieve the goals set out in the agenda by 2030. Governments are committed to establishing national frameworks for the achievement of the 17 Goals and to review progress using accessible quality data. With these goals in mind the Central Statistics Office (CSO) and Tailte Éireann are working together to link geography and statistics to produce indicators that help communicate and monitor Ireland’s performance in relation to achieving the 17 sustainable development goals.The indicator displayed supports the efforts to achieve goal number 3 which aims to ensure healthy lives and promote well-being for all at all ages.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs

Sociodemographic characteristics of the Irish and UK samples.

Pairwise comparisons for the Irish (N = 1,030) and UK (N = 2,020) samples.

Correlates of class membership in the Irish sample (N = 1,030).

IntroductionGuidelines for the management of rheumatoid arthritis (RA) recommend using influenza and pneumococcal vaccinations to mitigate infection risk. The level of adherence to these guidelines is not well known in the UK. The aims of this study were to describe the uptake of influenza and pneumococcal vaccinations in patients with RA in the UK, to compare the characteristics of those vaccinated to those not vaccinated and to compare vaccination rates across regions of the UK.MethodsA retrospective cohort study of adults diagnosed with incident RA and treated with non-biologic immunosuppressive therapy, using data from a large primary care database. For the influenza vaccination, patients were considered unvaccinated on 1st September each year and upon vaccination their status changed to vaccinated. For pneumococcal vaccination, patients were considered vaccinated after their first vaccination until the end of follow-up. Patients were stratified by age 65 at the start of follow-up, given differences in vaccination guidelines for the general population.ResultsOverall (N = 15,724), 80% patients received at least one influenza vaccination, and 50% patients received a pneumococcal vaccination, during follow-up (mean 5.3 years). Of those aged below 65 years (N = 9,969), 73% patients had received at least one influenza vaccination, and 43% patients received at least one pneumococcal vaccination. Of those aged over 65 years (N = 5,755), 91% patients received at least one influenza vaccination, and 61% patients had received at least one pneumococcal vaccination. Those vaccinated were older, had more comorbidity and visited the GP more often. Regional differences in vaccination rates were seen with the highest rates in Northern Ireland, and the lowest rates in London.ConclusionsOne in five patients received no influenza vaccinations and one in two patients received no pneumonia vaccine over five years of follow-up. There remains significant scope to improve uptake of vaccinations in patients with RA.

Dataset description

Daily official UK Covid data. The data is available per country (England, Scotland, Wales and Northern Ireland) and for different regions in England. The different regions are split into two different files as part of the data is directly gathered by the NHS (National Health Service). The files that contain the word 'nhsregion' in their name, include data related to hospitals only, such as number of admissions or number of people in respirators. The files containing the word 'region' in their name, include the rest of the data, such as number of cases, number of vaccinated people or number of tests performed per day. The next paragraphs describe the columns for the different file types.

Region files

Files related to regions (word 'region' included in the file name) have the following columns: - "date": date in YYYY-MM-DD format - "area type": type of area covered in the file (region or nation) - "area name": name of area covered in the file (region or nation name) - "daily cases": new cases on a given date - "cum cases": cumulative cases - "new deaths 28days": new deaths within 28 days of a positive test - "cum deaths 28days": cumulative deaths within 28 days of a positive test - "new deaths_60days": new deaths within 60 days of a positive test - "cum deaths 60days": cumulative deaths within 60 days of a positive test - "new_first_episode": new first episodes by date - "cum_first_episode": cumulative first episodes by date - "new_reinfections": new reinfections by specimen data - "cum_reinfections": cumualtive reinfections by specimen data - "new_virus_test": new virus tests by date - "cum_virus_test": cumulative virus tests by date - "new_pcr_test": new PCR tests by date - "cum_pcr_test": cumulative PCR tests by date - "new_lfd_test": new LFD tests by date - "cum_lfd_test": cumulative LFD tests by date - "test_roll_pos_pct": percentage of unique case positivity by date rolling sum - "test_roll_people": unique people tested by date rolling sum - "new first dose": new people vaccinated with a first dose - "cum first dose": cumulative people vaccinated with a first dose - "new second dose": new people vaccinated with a first dose - "cum second dose": cumulative people vaccinated with a first dose - "new third dose": new people vaccinated with a booster or third dose - "cum third dose": cumulative people vaccinated with a booster or third dose

Country files

Files related to countries (England, Northern Ireland, Scotland and Wales) have the above columns and also: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

NHS Region files

Files related to nhsregion (word 'nhsregion' included in the file name) have the following columns: - "new admissions": new admissions, - "cum admissions": cumulative admissions, - "hospital cases": patients in hospitals, - "ventilator beds": COVID occupied mechanical ventilator beds - "trans_rate_min": minimum transmission rate (R) - "trans_rate_max": maximum transmission rate (R) - "trans_growth_min": transmission rate growth min - "trans_growth_max": transmission rate growth max

It's worth noting that the dataset hasn't been cleaned and it needs cleaning. Also, different files have different null columns. This isn't an error in the dataset but the way different countries and regions report the data.

Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating protective humoral immune responses generated post-infection/post-vaccination. Here we describe a novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising Antibody (NAb) responses against live SARS-CoV-2 Wild Type and Variants of Concern (VOC) in convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT) was performed in 96-well plates using clinical isolates WT-B, WT-B.1.177.18 and/or VOCs Beta and Omicron. Plasma samples (All Ireland Infectious Diseases (AIID) Cohort) were serially diluted (8 points, half-log) from 1:20 and pre-incubated with SARS-CoV-2 (1h, 37°C). Virus-plasma mixture were added onto Vero E6 or Vero E6/TMPRSS2 cells for 18h. Percentage infected cells was analysed by automated flow cytometry following trypsinisation, fixation and SARS-CoV-2 Nucleoprotein intracellular staining. Half-maximal Neutralisation Titres (NT50) were determined using non-linear regression. Our assay was compared to Plaque Reduction Neutralisation Test (PRNT) and validated against the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Both Micro-NT and PRNT achieved comparable NT50 values. Further validation showed adequate correlation with PRNT using a panel of secondary standards of clinical convalescent and vaccinated plasma samples. We found the assay to be reproducible through measuring both repeatability and intermediate precision. Screening 190 convalescent samples and 11 COVID-19 naive controls (AIID cohort) we demonstrated that Micro-NT has broad dynamic range differentiating NT50s 1/5000. We could also characterise immune-escape VOC Beta and Omicron BA.5, achieving fold-reductions in neutralising capacity similar to those published. Our flow cytometry-based Micro-NT is a robust and reliable assay to quantify NAb titres, and has been selected as an endpoint in clinical trials.

The NT50s determined for each row are provided, as well the mean across all 25 measurements. The standard deviation (S) and co-efficient of variation (%CV) is provided for both the repeatability test (R) and the intermediate-precision (inter-assay) test (RW). The mean repeatability and intermediate precision is provided which an average of the 6 measurements.

Frequency and percentage of sample within occupation group by ethnic minority grouping.